Skip to content

Clinical observation of ear acupoint bean pressing combined with heat-sensitive moxibustion for allergic rhinitis under guidance of midday-midnight flowing theory

Clinical observation of ear acupoint bean pressing combined with heat-sensitive moxibustion for allergic rhinitis under guidance of midday-midnight flowing theory

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001416
Enrollment
Unknown
Registered
2025-07-16
Start date
2025-08-08
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

experimental group:ear acupoint bean pressing combined with?heat-sensitive moxibustion
control group:Conventional drug therapy

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Conforms to the diagnostic criteria for allergic rhinitis as described in the 'Guidelines for the Diagnosis and Treatment of Allergic Rhinitis in China (2022 Revised Edition)' and the National Higher Education Textbook Series on Traditional Chinese Medicine Industry 'Traditional Chinese Medicine Otorhinolaryngology' (Eleventh Edition); 2. Male or female aged 18-65 years; 3. Normal consciousness behavior coordination no other chronic diseases or mental diseases; 4. Deemed suitable for this study by the principal investigator; 5. Sign the informed consent form and commit to complete the entire follow-up process.

Exclusion criteria

Exclusion criteria: 1. Accompanied by acute and chronic nasosinusitis otitis media and other ear nose and throat infectious diseases; 2. Drug-induced rhinitis chronic epistaxis; 3. Anatomic abnormalities with severe deviation of nasal septum that significantly affect respiration; 4. Severe respiratory hematopoietic cardiovascular or psychiatric disorders; 5. Pregnant or lactating women with skin ulcers contact dermatitis and other skin diseases; 6.Ongoing or previous immunotherapy.

Design outcomes

Primary

MeasureTime frame
clinical efficacy;

Secondary

MeasureTime frame
Serum IgE content detection;Total Nasal Symptom Score;Nasal conjunctivitis quality of life questionnaire;Total No-Nasal Symptom Score;

Countries

China

Contacts

Public ContactZhang.Biaoxin

The First Affiliated Hospital of Anhui Medical University

532611328@qq.com18325596005

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026